Medicaid Generic Drugs: No Extra Rebates for Low-Cost Medicines.
This bill aims to prevent additional rebates for certain low-cost generic drugs within the Medicaid program. It means manufacturers of these drugs will not have to pay extra rebates if the unit price of the drug is less than $1. The goal is to maintain the availability of these medicines in the market, potentially affecting price stability and access to treatment for Medicaid beneficiaries.
Key points
The bill concerns generic (noninnovator) drugs in the Medicaid program.
Manufacturers will not be required to pay additional rebates for drugs with a unit price less than $1.
These changes are set to take effect from January 1, 2022.
The goal is to ensure that low-cost generic drugs remain available within the Medicaid program.
Expired
Citizen Poll